Cardiovascular protection and heart recovery
For endurance athletes, and master cyclists in particular, cardiovascular health is the foundation of everything. Beyond simply improving blood sugar levels, GLP-1s appear to have a direct, protective effect on the heart and vascular system.
Recent research indicates that GLP-1 medications can actively support the heart following major cardiac events. Studies show that these drugs help protect cardiac tissue and improve overall recovery after a heart attack. For riders looking to maintain long-term cardiovascular resilience well into their 50s, 60s, and beyond, this systemic heart protection is a significant bonus.
Preserving bone health under weight loss
Rapid weight loss normally comes with a hidden hazard for cyclists: a loss of bone mineral density. Because cycling is a non-impact, low-load sport, dedicated riders are already at a higher risk for lower bone density compared to runners or weightlifters. Dropping significant weight quickly can compound that risk, leaving bones more vulnerable to fractures.
Surprisingly, new clinical findings suggest that semaglutide (the active ingredient in Ozempic) may actually break this pattern. In a large real-world study presented at the Endocrine Society’s annual meeting in 2026, researchers found that patients taking semaglutide experienced a notable reduction in bone fracture riskdespite achieving substantial weight loss.
Rewiring the brain: addiction and impulse control
Perhaps the most fascinating emerging research involves how GLP-1s interact with the brain’s reward centres. The same mechanisms that quiet “food noise” in the brain appear to dampen other impulsive or compulsive behaviours as well.
Two major 2026 studies highlighted this unexpected neurological benefit: lower addiction and overdose risks. Researchers analysing large-scale health data found that patients on GLP-1 medications showed significantly lower risks of substance abuse, addiction, and accidental overdose.
Also, a separate study published in June 2026 linked Ozempic and Wegovy use to a surprising drop in aggressive and violent behaviors, pointing to improved overall emotional regulation and impulse control.
By dampening the brain’s dopamine-driven craving loops, these medications seem to help calm chronic mental chatter, whether that applies to food, alcohol or other compulsive habits.
The big picture
While weight loss might be what first piques a cyclist’s interest in GLP-1s, the broader health picture is far more compelling. The massive popularity of these medications has unlocked a wave of new data and research, and what scientists are discovering is truly fascinating. Pairing weight loss with the cardiovascular, skeletal, and neurological benefits of these drugs makes it easy to think of them as a catch-all cure. But what happens when you eventually stop taking them? In the next article, we’ll take a look at what life after meds looks like and how to make your progress last.
